Agenus (AGEN) Cash from Investing Activities (2010 - 2026)
Agenus' (AGEN) quarterly Cash from Investing Activities came in at $69.0 million in Q1 2026, up 120868.42% year-on-year from N/an in Q1 2025, and up 8740.0% quarter-over-quarter from $780000.0 in Q4 2025.
Agenus (AGEN) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Agenus' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $69.0 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 120868.42% year-over-year to $69.0 million in Q1 2026; TTM through Mar 2026 was $70.1 million, a 48437.24% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 4322.22% from the prior year.
- Cash from Investing Activities grew to $69.0 million in Q1 2026 per AGEN's latest filing, from $780000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $69.0 million in Q1 2026 and bottomed at -$15.6 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is $57000.0 (2025), against an average of $2.4 million.
- Across the five-year window, Cash from Investing Activities tumbled 3743.37% in 2022 and surged 120868.42% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at -$6.4 million in 2022, then surged by 144.24% to $2.8 million in 2023, then plunged by 100.74% to -$21000.0 in 2024, then surged by 3814.29% to $780000.0 in 2025, then surged by 8740.0% to $69.0 million in 2026.
- Per Business Quant, the three latest AGEN Cash from Investing Activities figures stand at $69.0 million (Q1 2026), $780000.0 (Q4 2025), and $76000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Agenus | 234.10 Mn | 199.10 Mn | 33.74 Mn | 68.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.95 Mn |
| Mar 31, 2026 | 68.95 Mn |
| Dec 31, 2025 | 780,000.00 |
| Dec 31, 2025 | 780,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Jun 30, 2025 | 281,000.00 |
| Jun 30, 2025 | 281,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Jun 30, 2024 | -237,000.00 |
| Jun 30, 2024 | -237,000.00 |
| Mar 31, 2024 | 229,000.00 |
| Mar 31, 2024 | 229,000.00 |
| Dec 31, 2023 | 2.82 Mn |
| Dec 31, 2023 | 2.82 Mn |